Table 10.
Spain.
| (A) | 06/01–09/20/2020 | |||
|---|---|---|---|---|
| Position | Location | Mutation | Count | Incidence |
| 241nt | 5´UTR | CG → TG | 133/135 | prevalent |
| noneffective | ||||
| 445nt | ORF1ab polyprotein → leader protein | TT → CT | 88/135 | CN,DE,FR |
| noneffective | ||||
| 3,037nt | nsp3 | CT → TT | 131/135 | prevalent |
| noneffective | ||||
| 5,572nt | GT → TT | 11/135 | unique | |
| ATGTAC (Methionine Tyrosine) → ATTTAC (Isoleucine Tyrosine) | ||||
| 5,784nt | CT → TT | 13/135 | unique | |
| ACT (Threonine) → ATT (Isoleucine) | ||||
| 6,286nt | CT → TT | 89/135 | DE,FR,ZA | |
| noneffective | ||||
| 14,408nt | RNA‐dependent RNA polymerase | CT → TT | 132/135 | prevalent |
| CCT (Proline) → CTT (Leucine) | ||||
| 20,268nt | endoRNAse | AG → GG | 26/135 | FR,RU,US,ZA |
| noneffective | ||||
| 21,255nt | 2´‐O‐ribose methyltransferase | GT → CT | 84/135 | DE,FR |
| noneffective | ||||
| 22,227nt | Spike glycoprotein | CT → TT | 89/135 | DE,FR,ZA |
| noneffective | ||||
| 22,297nt | TA → CA | 11/135 | RU | |
| noneffective | ||||
| 25,049nt | GA → TA | 18/135 | DE | |
| GAT (Aspartic Acid) → TAT (Tyrosine) | ||||
| 25,062nt | GT → TT | 18/135 | unique | |
| GGT (Glycine) → GTT (Valine) | ||||
| 26,801nt | Membrane glycoprotein | CA → GA | 89/135 | DE,FR,ZA |
| noneffective | ||||
| 27,944nt | ORF8 protein | CC → TC | 56/135 | FR |
| noneffective | ||||
| 27,982nt | CA → TA | 13/135 | unique | |
| CCA (Proline) → CTA (Leucine) | ||||
| 28,657nt | Nucleocapsid phosphoprotein | CG → TG | 19/135 | unique |
| noneffective | ||||
| 28,881nt | GGG → AAC | 14/135 | prevalent | |
| AGGGGA (Arginine Glycine) → AAACGA (Lysine Arginine) | ||||
| 28,932nt | CT → TT | 89/135 | unique | |
| GCT (Alanine) → GTT (Valine) | ||||
| 29,645nt | ORF10 protein | GT → TT | 89/135 | DE,FR |
| noneffective | ||||
| (B) | 01/19/2020–01/20/2021 | |||
|---|---|---|---|---|
| Position | Location | Mutation | Total Count | Percentage |
| 241nt | 5´UTR | C → T | 2,690 | 78.47 |
| 313nt | ORF1ab polyprotein → leader protein | C → T | 117 | 3.41 |
| 445nt | T → C | 858 | 25.03 | |
| 1,059nt | nsp2 | C → T | 122 | 3.56 |
| 1,987nt | A → G | 75 | 2.19 | |
| 3,037nt | nsp3 | C → T | 2,717 | 79.26 |
| 5,170nt | C → T | 141 | 4.11 | |
| 6,286nt | C → T | 861 | 25.12 | |
| 6,294nt | T → C | 82 | 2.39 | |
| 8,782nt | nsp4 | C → T | 601 | 17.53 |
| 9,477nt | T → A | 379 | 11.06 | |
| 11,083nt | nsp6 | G → T | 166 | 4.84 |
| 11,132nt | G → T | 137 | 4 | |
| 13,006nt | nsp9 | T → C | 77 | 2.25 |
| 14,408nt | RNA‐dependent RNA polymerase | C → T | 2,708 | 79 |
| 14,805nt | C → T | 408 | 11.9 | |
| 20,268nt | endoRNAse | A → G | 1,223 | 35.68 |
| 21,255nt | 2'‐O‐ribose methyltransferase | G → C | 780 | 22.75 |
| 22,227nt | Spike glycoprotein | C → T | 843 | 24.59 |
| 23,403nt | A → G | 2,731 | 79.67 | |
| 25,049nt | G → T | 71 | 2.07 | |
| 25,563nt | ORF3a | G → T | 147 | 4.29 |
| 25,688nt | C → T | 78 | 2.28 | |
| 25,979nt | G → T | 371 | 10.82 | |
| 26,088nt | C → T | 215 | 6.27 | |
| 26,144nt | G → T | 100 | 2.92 | |
| 26,801nt | Membrane glycoprotein | C → G | 855 | 24.94 |
| 27,944nt | ORF8 | C → T | 456 | 13.3 |
| 28,144nt | T → C | 599 | 17.47 | |
| 28,657nt | Nucleocapsid phosphoprotein | C → T | 441 | 12.86 |
| 28,863nt | C → T | 378 | 11.03 | |
| 28,881nt | G → A | 398 | 11.61 | |
| 28,882nt | G → A | 396 | 11.55 | |
| 28,883nt | G → C | 395 | 11.52 | |
| 28,932nt | C → T | 850 | 24.8 | |
| 29,645nt | ORF10 | G → T | 840 | 24.5 |
| 29,734nt | 3´UTR | G → C | 302 | 8.81 |
| 29,870nt | C → A | 107 | 3.12 | |
The general design of these Tables follows the outline described in detail in the legend to Table 5 (United States). The number of sequences investigated for SARS‐CoV‐2 mutations is detailed in Tables for individual countries.